The United States of America, as Represented by The Secretary, Department of Health and Human Services;AstraZeneca AB
发明人:
Barry, Simon,Kendrew, Jane,Ho, Tony,Wedge, Stephen Robert,Ivy, Susan Percy,Kohn, Elise,Lee, Jung-Min
申请号：
AU2017221268
公开号：
AU2017221268A1
申请日:
2017.02.14
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
Methods comprising repeating cycles of administration of a composition comprising cediranib according to a fixed intermittent dosing regimen comprising administration of an effective amount of the composition comprising cediranib on one or more consecutive days of a cycle followed by one or more consecutive days of rest on which said composition is not administered are disclosed herein, and may be used as monotherapy or may comprise administration of one or more partner drugs or therapies and may be used in combination therapy. Such methods may produce an antiangiogenic and/or vascular permeability reducing effect, treat at least one disease state associated with angiogenesis, reduce the total dose of cediranib required to provide effective VEGF inhibition, reduce adverse events and toxicity due to cediranib administration, maintain cover on the VEGF pathway despite reduction of total doses of cediranib, and/or increase repair of healthy, non-cancerous tissue during treatment of cancer using combination therapies.
